Takeda Pharmaceutical (TAK) Change in Accured Expenses (2021 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Change in Accured Expenses of -$219.0 million for Q2 2026, down 80.75% year-over-year from -$1.1 billion in Q2 2025, and down 364.02% quarter-over-quarter from $82.9 million in Q3 2025.
Takeda Pharmaceutical (TAK) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Takeda Pharmaceutical's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$219.0 million for Q2 2026.
- In Q2 2026, Change in Accured Expenses fell 80.75% year-over-year to -$219.0 million; the TTM figure through Jun 2026 stood at -$217.2 million (down 149.2% YoY), while the FY2026 annual figure was -$542.1 million, down 2267.54% from the prior year.
- Change in Accured Expenses for Q2 2026 stood at -$219.0 million, down from $82.9 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $82.9 million in Q3 2025, with the low at -$341.4 million in Q2 2022.
- The 4-year median for Change in Accured Expenses is -$57.7 million (2024), against an average of -$80.7 million.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses tumbled 368.04% in 2022, then surged 169.36% in 2025.
- Takeda Pharmaceutical's Change in Accured Expenses stood at -$341.4 million in 2022, then surged by 115.14% to $51.7 million in 2024, then surged by 60.46% to $82.9 million in 2025, then tumbled by 364.02% to -$219.0 million in 2026.
- Business Quant data shows TAK's Change in Accured Expenses at -$219.0 million in Q2 2026, $82.9 million in Q3 2025, and -$121.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | 41.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -219.00 Mn |
| Jun 30, 2026 | -219.00 Mn |
| Sep 30, 2025 | 82.95 Mn |
| Sep 30, 2025 | 82.95 Mn |
| Jun 30, 2025 | -121.16 Mn |
| Jun 30, 2025 | -121.16 Mn |
| Mar 31, 2025 | 40.04 Mn |
| Mar 31, 2025 | 40.04 Mn |
| Dec 31, 2024 | 51.69 Mn |
| Dec 31, 2024 | 51.69 Mn |
| Mar 31, 2024 | -57.72 Mn |
| Mar 31, 2024 | -57.72 Mn |
| Jun 30, 2022 | -341.40 Mn |
| Jun 30, 2022 | -341.40 Mn |
| Jun 30, 2021 | -72.94 Mn |
| Jun 30, 2021 | -72.94 Mn |